Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sotalol
Drug ID BADD_D02060
Description Sotalol is a methanesulfonanilide developed in 1960.[A178579] It was the first of the class III anti arrhythmic drugs.[A178579] Sotalol was first approved as an oral tablet on 30 October 1992.[L6334] A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm in atrial fibrillation or flutter.[Label,L6373,L6376]
Indications and Usage Sotalol is indicated to treat life threatening ventricular arrhytmias and maintain normal sinus rhythm in patients with atrial fibrillation or flutter.[Label] There are also oral solutions and intravenous injections indicated for patients requiring sotalol, but for whom a tablet would not be appropriate.[Label,L6373,L6376]
Marketing Status approved
ATC Code C07AA07
DrugBank ID DB00489
KEGG ID D08525
MeSH ID D013015
PubChem ID 5253
TTD Drug ID D04VMT
NDC Product Code Not Available
UNII A6D97U294I
Synonyms Sotalol | Sotalol Hydrochloride | Sotalol Monohydrochloride | MJ-1999 | MJ 1999 | MJ1999 | Darob
Chemical Information
Molecular Formula C12H20N2O3S
CAS Registry Number 3930-20-9
SMILES CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Vasodilation procedure25.03.01.001--Not Available
Angiopathy24.03.02.007--Not Available
Appetite disorder19.09.01.002; 14.03.01.004--Not Available
Cardiac disorder02.11.01.0030.000281%Not Available
Hyperinsulinism14.06.03.007; 05.06.03.007--Not Available
Ischaemic stroke24.04.06.010; 17.08.01.0180.000562%Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.0010.000422%
Adverse drug reaction08.06.01.0090.000984%Not Available
Disease recurrence08.01.03.0500.000562%Not Available
Drug intolerance08.06.01.0130.001040%Not Available
Pulmonary toxicity22.01.02.007; 12.03.01.0130.000703%Not Available
Hyperlipidaemia14.08.03.001--
Metabolic encephalopathy17.13.01.001; 14.11.01.0130.000281%Not Available
Renal impairment20.01.03.0100.000422%Not Available
Non-cardiac chest pain22.12.02.009; 08.01.08.006--
Treatment failure08.06.01.0170.002109%Not Available
Organising pneumonia22.01.02.0080.000703%Not Available
Low birth weight baby18.04.02.0030.000562%Not Available
Oropharyngeal discomfort22.12.03.015; 07.05.05.008--Not Available
Oropharyngeal pain22.12.03.016; 07.05.05.004--
Acute kidney injury20.01.03.0160.001687%
Acute left ventricular failure02.05.02.0050.000281%Not Available
Abdominal wall haematoma24.07.02.039; 07.16.05.0050.000422%Not Available
Foetal hypokinesia18.03.02.0150.000422%Not Available
Pneumonia lipoid22.01.01.0300.000281%Not Available
Therapeutic product effect incomplete08.06.01.0520.000422%Not Available
Therapy non-responder08.06.01.0630.002418%Not Available
The 7th Page    First    Pre   7    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene